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KPC-3-producing bacteria are endemic in many countries but only recently became
apparent their wide distribution in different Portuguese hospitals. The aim of this study
is to characterize genetic backgrounds associated with blaKPC−3 among Klebsiella
pneumoniae isolates recently identified on non-hospitalized patients in Portugal. Twenty
KPC-producing K. pneumoniae identified between October 2014 and November 2015
in three different community laboratories were characterized. Isolates were mainly from
patients from long-term care facilities (n = 11) or nursing homes (n = 6), most of
them (75%) previously hospitalized in different Portuguese hospitals. Standard methods
were used for bacterial identification and antibiotic susceptibility testing. Carbapenemase
production was assessed by the Blue-Carba test, and identification of bla genes was
performed by PCR and sequencing. Epidemiological features of KPC-producing K.
pneumoniae included population structure (XbaI-PFGE, MLST and wzi sequencing),
genetic context (mapping of Tn4401), and plasmid (replicon typing, S1-PFGE, and
hybridization) analysis. All K. pneumoniae isolates produced KPC-3, with two MDR
K. pneumoniae epidemic clones representing 75% of the isolates, namely ST147
(wzi64/K14.64, February–November 2015) and ST15 (two lineages exhibiting capsular
types wzi19/K19 or wzi93/K60, July-November 2015). Other sporadic clones were
detected: ST231 (n= 3;wzi104), ST348 (n= 1;wzi94) and ST109 (n= 1,wzi22/K22.37).
blaKPC−3 was identified within Tn4401d in all isolates, located in most cases (80%) on
cointegrated plasmids (repAFIA+repAFII+oriColE1;105-250 kb) or in 50 kb IncN plasmids.
In conclusion, this study highlights a polyclonal structure of KPC-3-producing K.
pneumoniae and the predominance of the ST147 clone among non-hospitalized patients
in Portugal, linked to platforms still unnoticed in Europe (blaKPC−3-Tn4401d-IncFIA) or
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firstly reported (blaKPC−3-Tn4401d-IncN). This scenario underlines the recent penetration
of successful mobile genetic elements in previously circulating MDR K. pneumoniae
lineages (mainly ST147 and ST15) in Portugal, rather than the importation of the global
lineages from clonal group 258.
Keywords:multidrug resistance, carbapenemases, international clones, ST15, ST147, cointegrated plasmids, ColE
INTRODUCTION
In the last years, carbapenem-resistant Enterobacteriaceae
have spread globally, being responsible for high rates
of morbidity and mortality among healthcare-associated
infections, mainly due to the depletion of effective
therapeutic options (WHO, 2014; Albiger et al., 2015,
http://www.cdc.gov/drugresistance/threat-report-2013/). After
the first strain identified in 1996 in a North Carolina hospital
(USA; Yigit et al., 2001), Klebsiella pneumoniae carbapenemases
(KPCs) have exploded worldwide predominantly among K.
pneumoniae isolates (Munoz-Price et al., 2013; Chen et al.,
2014b). To date, 23 KPC variants (KPC-2 to KPC-24) have
been described (http://www.lahey.org/Studies/other.asp#table
1), being KPC-2 and KPC-3 the most widespread variants
with variable geographic distribution (Munoz-Price et al.,
2013; Nordmann and Poirel, 2014). While in some countries
(USA, Colombia, Italy, and Israel) both KPC-2- and KPC-3-
producing bacteria are endemic, in others (Argentina, Brazil,
Greece, Poland, and China) KPC-2 producers are predominant
(Munoz-Price et al., 2013; Albiger et al., 2015).
The blaKPC genes are commonly located on Tn4401, a
10 kb Tn3-like transposon delimited by two 39-bp imperfect
inverted repeat sequences harboring blaKPC, transposase and
resolvase genes, and insertion sequences ISKpn7 (upstream
blaKPC) and ISKpn6 (downstream blaKPC; Chen et al., 2014b).
It is recognized as a highly active transposon enhancing the
spread of blaKPC genes to different plasmid scaffolds (Cuzon
et al., 2011). To date, six Tn4401 isoforms have been described
with variable deletions between ISKpn7 and blaKPC providing
different promoter regions to the gene (a,−99 bp; b, no deletion;
c, −215 bp; d, −68 bp; e, −255 bp; g, equal to isoform c
but with one single nucleotide mutation on P2 promotor),
and consequently different expression levels of the blaKPC gene
(Naas et al., 2012; Chmelnitsky et al., 2014). Besides its genetic
environment, other factors are known to have greatly contributed
to the spread of KPC producers in many countries, leading to an
increasing challenge in the design of effective infection control
measures. First, the introduction and subsequent expansion
of blaKPC−2 and blaKPC−3 on multidrug resistant (MDR) K.
pneumoniae lineages from clonal group (CG) 258 [sequence
types (ST) 11, 258, 512] (Munoz-Price et al., 2013; Chen
et al., 2014b), followed in a few countries (e.g., Israel, Italy,
Colombia) by subsequent dispersion to other clonal backgrounds
(Baraniak et al., 2015; Bonura et al., 2015; Ocampo et al., 2015).
Second, the acquisition of blaKPC by plasmids from different
incompatibility groups (IncFIIK2, IncFIA, IncI2, IncN, IncX3,
ColE), favored a quick intra- and inter-species dissemination
(Chen et al., 2014b).
In Portugal, KPC-2 was identified only in an environmental
Escherichia coli isolate in 2010 (Poirel et al., 2012), while KPC-
3 producers were first detected in 2009 in a central hospital
(Machado et al., 2010). However, only recently became evident
the widespread distribution of KPC-3 among K. pneumoniae
isolates in different Portuguese hospitals (Silva et al., unpublished
data; Manageiro et al., 2015). In this study, we aim to trace the
landscape of KPC-3-producing K. pneumoniae isolates recently
identified outside hospital boundaries in Portugal by detailed
characterization of clonal and plasmid genetic backgrounds.
MATERIALS AND METHODS
Bacterial Isolates and Epidemiological
Data
Thirty K. pneumoniae isolates showing reduced susceptibility
to carbapenems were identified between October 2014 and
November 2015 in three different community laboratories in the
North of Portugal, one of them receiving samples from all over
the country. Twenty of them were identified as KPC producers
and further characterized in this study. They were detected in
urine samples (n = 19) or sputum (n = 1) of patients between
61 and 89 years old (mean age = 83; 16 females, 4 males;
Table 1). Most of these patients were institutionalized in long-
term care facilities (LTCFs) [n = 11; 55%; six different LTCFs
(A–F)] or nursing homes (NH) [n = 6; 30%; five different NH
(A–E)], while some were identified in ambulatory (n = 3; 15%;
Table 1). Most of them (n= 13; 65%) had been hospitalized in the
previous month in different hospitals from the North or Centre
of Portugal, although in three cases no hospitalization or older
hospitalization events (4–9 months) were detected (Table 1).
Travel history abroad was discarded for 60% of the patients (n =
12/20), or considered improbable for the remaining patients due
to their clinical conditions (impaired mobilization and chronic
underlying diseases).
Antibiotic Resistance Phenotypes and
Genotypes
Bacterial identification and preliminary antibiotic susceptibility
testing were performed by Vitek II system (BioMérieux,
Marcy l’Étoile, France). Confirmatory and additional tests for
β-lactams (amoxicillin-clavulanic acid, mecillinam, cefoxitin,
extended-spectrum cephalosporins, aztreonam, carbapenems),
aminoglycosides (amikacin, gentamicin, netilmicin,
tobramycin), fluoroquinolones (ciprofloxacin), folate pathway
inhibitors (trimethoprim, trimethoprim-sulfamethoxazole),
chloramphenicol, fosfomycin, and colistin were assessed by
standard disc diffusion (Oxoid Ltd., Basingstoke, United
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Kingdom), agar dilution (for fosfomycin; in the presence of
glucose-6-phosphate at 25 mg/L), broth microdilution (for
colistin) or E-test (for carbapenems) (Liofilchem, Italy) methods
according to EUCAST (www.eucast.org).
Production of carbapenemases was assessed by the Blue-Carba
test (Pires et al., 2013), and identification of carbapenemases
(blaNDM, blaVIM, blaIMP, blaKPC,blaOXA−48),or other bla genes
(blaCTX−M, blaSHV, blaTEM, blaOXA) was performed by PCR and
sequencing (Curiao et al., 2010; Bogaerts et al., 2013; Rodrigues
et al., 2014).
Population Structure Analysis
Population structure characterization included XbaI-Pulsed-
Field Gel Electrophoresis (PFGE) (electrophoresis conditions:
5–20 s for 4 h and 25–50 s for 18 h, 14◦C, 6 V/cm2),
and multi-locus sequence typing (MLST) (http://bigsdb.
web.pasteur.fr/klebsiella/primers_used.html) in representative
isolates, as described (Rodrigues et al., 2014). Molecular capsule
typing was performed by PCR and sequencing ofwzi gene (Brisse
et al., 2013).
Characterization of the Genetic
Environment and Location of blaKPC Genes
The genetic context of blaKPC−3 was investigated by PCR and
sequencing targeting Tn4401 conserved sequences (Chen et al.,
2014a). Location of bla (blaKPC−3, blaCTX−M−15) genes and
plasmid characterization were assessed by S1- and I-CeuI-PFGE
and identification of replication genes by PCR, sequencing and
hybridization (Carattoli et al., 2005; García-Fernández et al.,
2009; Villa et al., 2010; Chen et al., 2014a; Rodrigues et al., 2014).
RESULTS
Carbapanemase Production and Variable
Antibiotic Resistance Phenotypes
All isolates produced KPC-3 and demonstrated resistance
or intermediate phenotypes to ertapenem (MIC = 1 to 16
mg/L), and susceptible, intermediate or resistance phenotypes
to imipenem (MIC = 2 to 16 mg/L) and meropenem
(MIC = 1 to 8 mg/L), with colonies growing within the
inhibition zone of all carbapenems tested, a hetero-resistance
phenotype usually observed for KPC producers (Nordmann
et al., 2009; Table 2). Although for some isolates the MIC
values for imipenem and meropenem were interpreted
as susceptible by the clinical breakpoints defined by
EUCAST, in all cases they were above the epidemiological
cut-off values (ECOFFs) defined for K. pneumoniae
(http://www.eucast.org/mic_distributions_and_ecoffs/; Table 2).
All isolates were defined as multidrug resistant (MDR) in
accordance with the definition of MDR for Enterobacteriaceae
(non-susceptible to ≥1 agent in ≥3 antimicrobial categories;
Magiorakos et al., 2012), although some of them exhibited a less
extensive resistance profile to non-β-lactams, being resistant only
to ciprofloxacin (Table 2). All isolates were susceptible to colistin
(MIC= 0.25–2 mg/L; Table 2).
KPC-3 was Identified Among Locally
Circulating K. pneumoniae Clones
KPC-3-producing K. pneumoniae isolates were assigned to six
different PFGE-types (arbitrarily designated as Kp1 to Kp6),
each one of them linked to a specific capsular type (Table 1).
Most isolates belonged to ST147 carrying wzi64 (K14.64; n =
10 Kp1, 50%; detected between February to November 2015)
and produced additionally SHV-11 (n = 9) or SHV-28 (n =
1), OXA-9 (n = 6) and/or TEM-1 (n = 1; Table 1). Some
(n = 4) of these patients had recently been hospitalized in
hospitals (A and D) where KPC-3-producing ST147 isolates
exhibiting the same PFGE-type were detected (data not shown,
Silva et al., unpublished data). ST15 was also frequent (n =
5, 25%), with two different clones being identified (n = 4
Kp2 carrying wzi19/K19; and n = 1 Kp3 carrying wzi93/K60)
between July and November 2015. These isolates co-produced
OXA-9 and SHV-28. All ST15-Kp2 were identified in patients
from the same LTCF or region, and in one case there was
no previous hospitalization (Table 2). ST231 isolates carrying
wzi104 (n = 3 Kp4; October 2015) co-produced SHV-1 and
TEM-1 (n = 1), and were identified in patients for which no
epidemiological link could be established. Sporadic clones such
as ST348 carrying wzi94 (n = 1 Kp5; October 2014) or ST109
carrying wzi22 (K22.37; n = 1 Kp6; September 2015) producing
other β-lactamases were also detected (Table 1).
IncFIA and IncN Plasmids Involved in the
Dissemination of blaKPC-3-Tn4401d
In all isolates, the blaKPC−3 was identified between ISKpn7
(upstream) and ISKpn6 (downstream), in a structure previously
described as Tn4401 isoform d, known to have a 68bp deletion
between ISKpn7 and blaKPC gene (Chen et al., 2014b). Isolates
showed a variable number of plasmids (2–5 plasmids) with
different sizes (40–500 kb), frequently from IncFIIK and IncR
families. In most of the cases (n = 16/20 isolates from different
clones), blaKPC−3 was located within cointegrated plasmids (105
to 250 kb) carrying repAFIA (100% identity with that of pBK30661
plasmid, GenBank accession number KF954759), repAFII (100%
identity with that of pBK30683 plasmid, GenBank accession
number KF954760), and oriColE1 (100% identity with ori p15 gene
pKBuS13 plasmid, GenBank accession number KM076933). In
the remaining isolates (n = 4/20 isolates belonging to ST147),
blaKPC−3 was identified in a ca. 50 kb IncN plasmid [repN
showing 100% identity with that of pKPC_FCF/3SP plasmid
(defined by pMLST as repN allele 7; ST15), GenBank accession
number CP004367] (Table 1). The two isolates for which a
less extended resistance profile was observed (Table 2) carried
blaKPC−3 within IncN plasmids and no additional IncF plasmids
were observed. The blaCTX−M−15 (when present) was variably
located in a ca. 200 kb-IncFIIK7 (ST348) or in a ca. 60 kb-IncR
(ST15-Kp3) plasmid type.
DISCUSSION
In this study, we highlight a polyclonal structure of KPC-
3 producing K. pneumoniae isolates among patients outside
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TABLE 2 | Antimicrobial resistance patterns of KPC-3-producing K. pneumoniae clones.
Antimicrobial % of Resistance (MIC range, mg/L)a,b
All ST147 ST15-Kp2 ST15-Kp3 ST231 ST348 ST109
(n = 20) (n = 10) (n = 4) (n = 1) (n = 3) (n = 1) (n = 1)
Amoxicillin/clavulanic acid 100 100 100 100 100 100 100
Mecillinam 100 100 100 100 100 100 100
Ceftazidime 100 100 100 100 100 100 100
Cefotaxime 100 100 100 100 100 100 100
Cefepime 100 100 100 100 100 100 100
Cefotaxime 85 80 100 100 100 100 0
Aztreonam 100 100 100 100 100 100 100
Ertapenem 100 (1–16) 100 (1–4) 100 (4–16) 100 (8) 100 (4–8) 100 (8) 100 (1)
Imipenem 75 (2–16) 100 (4–8) 25 (2–8) 100 (8) 33 (2–8) 100 (16) 100 (4)
Meropenem 40 (1–8) 20 (1–4) 25 (2–4) 100 (8) 67 (2–8) 100 (4) 100 (4)
Amikacin 50 60 75 0 33 0 0
Gentamicin 70 70 100 0 67 100 0
Netilmicin 75 70 100 100 67 100 0
Tobramycin 80 70 100 100 100 100 0
Ciprofloxacin 95 100 100 100 100 100 0
Sulfamethoxazole/trimethoprim 90 80 100 100 100 100 100
Trimethoprim 90 80 100 100 100 100 100
Chloramphenicol 35 0 75 100 100 0 0
Fosfomycin 15 10 0 100 0 100 0
Colistin 0 0 0 0 0 0 0
aAll intermediate isolates were considered as resistant.
bClinical Breakpoints (Ertapenem - S≤0.5 mg/L; Imipenem and Meropenem - S≤2 mg/L) and ECOFF values (Ertapenem - WT≤0.064 mg/L; Imipenem - WT≤1 mg/L; Meropenem -
WT≤0.125 mg/L) for MIC defined by EUCAST for K. pneumoniae.
hospital boundaries in Portugal consistent with nosocomial
acquisition, and unveil novel or uncovered plasmid backbones
carrying blaKPC−3 in Europe.
The first clinical cases of KPC-3 producers in Portugal were
detected in 2009 in a pediatric unit of a hospital from the
Lisbon and Tagus Valley region and involved 2 K. pneumoniae
belonging to ST11 (Machado et al., 2010). Months later and
until 2011, an outbreak involving 41 KPC-3-producing isolates,
most of them (n = 29) assigned to ST14, was reported (Calisto
et al., 2012). More recently, a nationwide study reported 22
K. pneumoniae producing KPC-3 (mainly ST11, ST14, ST15,
and ST147 clones) in several hospitals between 2010 and
2013 but plasmid backgrounds had been poorly characterized
(Manageiro et al., 2015). However, the situation concerning
carbapenemase-producing Enterobacteriaceae in Portugal was
only recently recognized in the EuSCAPE survey, where our
country appeared in level 2b (sporadic hospital outbreaks)
mainly due to the expansion of KPC producers (Albiger et al.,
2015). The data presented in this study strengthens an ongoing
dissemination of KPC-3 producers in Portugal, where the
identification of these bacteria among such a high diversity
of healthcare institutions other than hospitals might potentiate
their impact for both hospital and community settings. It is
thus advisable a reinforcement of infection control measures,
surveillance, and tracking of isolates resistant to carbapenems
in clinical institutions, and a coordinated action between
clinicians, epidemiologists and national reference laboratories
for guidance and harmonization of protocols (Albiger et al.,
2015).
We observed a polyclonal structure of KPC-3-producing
K. pneumoniae isolates, where most of the clones identified
(ST15, ST147, ST348) exhibited the same PFGE-pattern as
CTX-M-15 (ST348, ST15-Kp2, and -Kp3) or SHV-12 (ST147)
producers previously involved in hospital- and community-
acquired infections at least in the North region of Portugal
(2010–2012; Rodrigues et al., unpublished data; Rodrigues
et al., 2014). These “high-risk clones” have been linked to
the worldwide expansion of different ESBL (CTX-M-15 and
different SHV-types) and carbapenemases (KPC, VIM, NDM,
OXA-48-like), including in Portugal (Rodrigues et al., 2014).
This scenario suggests recent acquisition of blaKPC−3 by MDR
K. pneumoniae genetic lineages that were already circulating
in Portugal (ST15, ST147, ST231, ST348), a situation observed
less frequently than the amplification of CG258 lineages
(Baraniak et al., 2015; Bonura et al., 2015; Ocampo et al.,
2015).
The ST147 clone [clonal group (CG) 147] exhibiting capsular
type K14.K64 was identified in patients from diverse LTCFs and
NHs for a long period of time and seems to be the predominant
lineage among KPC-3-producing K. pneumoniae in different
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healthcare settings (Silva et al., unpublished data; Manageiro
et al., 2015). In fact, identical KPC-3-producing ST147 isolates
were recently involved in outbreaks in hospitals where some
of the patients had been previously hospitalized. Although,
nosocomial acquisition is the most probable origin for most
KPC-3 producers identified in patients included in this study,
it is of notice that in three cases no obvious hospitalization
link could be established. Indeed, considering the frequent
displacement of these patients between institutions (integrated
network of LTCFs in Portugal) and hospitals (we had only access
to the last hospitalization event) and that intestinal colonization
might be persistent in time (Feldman et al., 2013), we cannot
completely discard cross transmission events in the units
analyzed.
The identification of two distinct ST15 (CG15) lineages
in this study (ST15-K19 and ST15-K60) is in line with
recent studies based on wzi-capsule typing unveiling the
circulation of distinct lineages within this CG, that might have
differences in their relative occurrence, geographical, or niche
distribution and/or host susceptibility (Bialek-Davenet et al.,
2014; Holt et al., 2015; Rodrigues et al., 2015; Zhou et al., 2015,
http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html). The
ST231 K. pneumoniae clone (CG231) had already been linked to
GES-5 plus SHV-12 production in Portugal (Manageiro et al.,
2015) and its association with community invasive infections
(sepsis, lethal pneumonia, or meningitis), and high content in
virulence and antimicrobial resistance genes have recently been
highlighted (Holt et al., 2015). The ST109 clone is rarely reported
(http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html) and it is
described for the first time in Portugal. However, it belongs to the
CG17, associated with the expansion of CTX-M-15 and different
carbapenemases worldwide (Rodrigues et al., 2014; Holt et al.,
2015).
The blaKPC−3 was linked to Tn4401d isoform in all
characterized KPC-3-producing Enterobacteriaceae from
Portugal (this study; Manageiro et al., 2015). In this study, we
show that in most cases (80%) Tn4401d-blaKPC−3 was located
within cointegrated FIA, FII, and ColE1 plasmids (105–250
kb; Table 1) corroborating the strong association between
Tn4401d-blaKPC−3 with IncFIA plasmids pointed out previously
in large collections from the USA (Chen et al., 2014a; Deleo
et al., 2014; Bowers et al., 2015; Chavda et al., 2015). We detected
FIA and FII replicons identical to those of pBK30683 plasmid
(GenBank accession number KF954760) plus an additional
oriColE1 gene identical to that of the ColE1 plasmid pKBuS13
(GenBank accession number KM076933), supporting the role
of these mobilizable plasmids in the assembly of MDR plasmids
(Chen et al., 2014a; Garbari et al., 2015). These and other (IncFIA
plus IncA/C2 or IncFIA plus IncX3) cointegration forms seem
to play an important role in the intra- and inter-species spread
of carbapenem resistance genes (Chen et al., 2014a,b; Chavda
et al., 2015). To the best of our knowledge, we unveil for the first
time a cointegrate IncFIA platform carrying Tn4401d-blaKPC−3
in Europe, characterized and highly represented by far only in
isolates from the USA (mainly among non-ST258 and non-K.
pneumoniae isolates; Chen et al., 2014a). In the remaining
isolates (20%, 4 ST147), blaKPC−3-Tn4401d was located on ca.
50 kb IncN plasmids, an association primarily described in this
study.
In conclusion, this study highlights a polyclonal structure
among KPC-3 producers identified in geographically dispersed
non-hospitalized patients in Portugal, not always linked
to nosocomial acquisition, a situation that deserves close
monitoring due to its high clinical or epidemiological impact. In
all cases, a common platform (blaKPC−3-Tn4401d) was identified
in plasmids still unnoticed in Europe (blaKPC−3-Tn4401d-
IncFIA) or firstly reported here (blaKPC−3-Tn4401d-IncN).
Their identification in previously circulating MDR K.
pneumoniae lineages in our area (ST147, ST15, ST231, ST348)
underlines the recent penetration of successful mobile genetic
elements in locally circulating clonal backgrounds, rather than
the importation of the most common global lineages from
CG258.
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